Exact Sciences Co. (NASDAQ:EXAS) Shares Sold by Woodline Partners LP

Woodline Partners LP decreased its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 15.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 331,988 shares of the medical research company's stock after selling 59,467 shares during the period. Woodline Partners LP owned about 0.18% of Exact Sciences worth $18,654,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Capital World Investors raised its stake in Exact Sciences by 10.7% in the 4th quarter. Capital World Investors now owns 17,537,617 shares of the medical research company's stock valued at $985,439,000 after purchasing an additional 1,696,321 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Exact Sciences by 74.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,760,241 shares of the medical research company's stock worth $323,669,000 after acquiring an additional 2,462,165 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its stake in shares of Exact Sciences by 25.8% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,269,823 shares of the medical research company's stock worth $239,922,000 after acquiring an additional 876,985 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Exact Sciences by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 3,122,798 shares of the medical research company's stock worth $175,165,000 after purchasing an additional 16,828 shares during the last quarter. Finally, Spyglass Capital Management LLC increased its position in shares of Exact Sciences by 10.2% during the 4th quarter. Spyglass Capital Management LLC now owns 1,539,436 shares of the medical research company's stock worth $86,501,000 after purchasing an additional 142,343 shares during the last quarter. Hedge funds and other institutional investors own 88.82% of the company's stock.

Analyst Upgrades and Downgrades

EXAS has been the subject of a number of research analyst reports. Mizuho assumed coverage on Exact Sciences in a report on Thursday, April 10th. They set an "outperform" rating and a $60.00 target price for the company. Robert W. Baird raised their target price on Exact Sciences from $69.00 to $72.00 and gave the stock an "outperform" rating in a research report on Friday, May 2nd. William Blair reaffirmed an "outperform" rating on shares of Exact Sciences in a research report on Thursday, February 20th. Guggenheim reissued a "buy" rating and issued a $60.00 target price on shares of Exact Sciences in a report on Friday, April 11th. Finally, Royal Bank of Canada lifted their price target on Exact Sciences from $52.00 to $54.00 and gave the company a "sector perform" rating in a research note on Friday, May 2nd. Two investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Exact Sciences has an average rating of "Moderate Buy" and a consensus target price of $70.90.

Exact Sciences Trading Down 1.3%

Exact Sciences stock traded down $0.75 during trading on Tuesday, hitting $56.20. The company's stock had a trading volume of 412,807 shares, compared to its average volume of 2,551,855. The stock has a market capitalization of $10.60 billion, a price-to-earnings ratio of -10.08 and a beta of 0.92. The stock's fifty day moving average is $47.81 and its 200 day moving average is $51.87. Exact Sciences Co. has a 1-year low of $39.97 and a 1-year high of $72.83. The company has a debt-to-equity ratio of 0.97, a quick ratio of 1.93 and a current ratio of 2.15.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last released its earnings results on Thursday, May 1st. The medical research company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.16. The firm had revenue of $706.79 million during the quarter, compared to analyst estimates of $688.58 million. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. The business's quarterly revenue was up 10.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.60) earnings per share. As a group, equities research analysts predict that Exact Sciences Co. will post -0.58 EPS for the current year.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.